ABHD6: Its Place in Endocannabinoid Signaling and Beyond

Jessica K. Cao; Joshua Kaplan; Nephi Stella

doi:10.1016/j.tips.2019.02.002

ABHD6: Its Place in Endocannabinoid Signaling and Beyond

Jessica K. Cao, Joshua Kaplan, Nephi Stella

Research output: Contribution to journal › Review article › peer-review

36 Scopus citations

Abstract

The endocannabinoid (eCB) signaling system modulates neurotransmission and inflammation, among other physiological functions. Its newest member, α/β-hydrolase domain-containing 6 (ABHD6), has emerged as a promising therapeutic target to treat several devastating diseases, including epilepsy. Here, we review the molecular mechanisms that mediate and control eCB signaling and, within it, the specific role of ABHD6. We also discuss how ABHD6 controls the abundance of additional lipids and the trafficking of ionotropic receptors to plasma membranes. We finish with several unexplored questions regarding this novel enzyme. Our current understanding of the molecular mechanism and biological function of ABHD6 provides a strong foundation for the development of small-molecule therapeutics to treat devastating diseases.

Original language	English (US)
Pages (from-to)	267-277
Number of pages	11
Journal	Trends in pharmacological sciences
Volume	40
Issue number	4
DOIs	https://doi.org/10.1016/j.tips.2019.02.002
State	Published - Apr 2019
Externally published	Yes

Keywords

ABHD6
endocannabinoids
enzyme
epilepsy
neuroinflammation
neurons

ASJC Scopus subject areas

Toxicology
Pharmacology

Access to Document

10.1016/j.tips.2019.02.002

Cite this

@article{2f49c6ce6d04425a9cb6ef73993a9e3f,

title = "ABHD6: Its Place in Endocannabinoid Signaling and Beyond",

abstract = "The endocannabinoid (eCB) signaling system modulates neurotransmission and inflammation, among other physiological functions. Its newest member, α/β-hydrolase domain-containing 6 (ABHD6), has emerged as a promising therapeutic target to treat several devastating diseases, including epilepsy. Here, we review the molecular mechanisms that mediate and control eCB signaling and, within it, the specific role of ABHD6. We also discuss how ABHD6 controls the abundance of additional lipids and the trafficking of ionotropic receptors to plasma membranes. We finish with several unexplored questions regarding this novel enzyme. Our current understanding of the molecular mechanism and biological function of ABHD6 provides a strong foundation for the development of small-molecule therapeutics to treat devastating diseases.",

keywords = "ABHD6, endocannabinoids, enzyme, epilepsy, neuroinflammation, neurons",

author = "Cao, {Jessica K.} and Joshua Kaplan and Nephi Stella",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = apr,

doi = "10.1016/j.tips.2019.02.002",

language = "English (US)",

volume = "40",

pages = "267--277",

journal = "Trends in pharmacological sciences",

issn = "0165-6147",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - ABHD6

T2 - Its Place in Endocannabinoid Signaling and Beyond

AU - Cao, Jessica K.

AU - Kaplan, Joshua

AU - Stella, Nephi

PY - 2019/4

Y1 - 2019/4

N2 - The endocannabinoid (eCB) signaling system modulates neurotransmission and inflammation, among other physiological functions. Its newest member, α/β-hydrolase domain-containing 6 (ABHD6), has emerged as a promising therapeutic target to treat several devastating diseases, including epilepsy. Here, we review the molecular mechanisms that mediate and control eCB signaling and, within it, the specific role of ABHD6. We also discuss how ABHD6 controls the abundance of additional lipids and the trafficking of ionotropic receptors to plasma membranes. We finish with several unexplored questions regarding this novel enzyme. Our current understanding of the molecular mechanism and biological function of ABHD6 provides a strong foundation for the development of small-molecule therapeutics to treat devastating diseases.

AB - The endocannabinoid (eCB) signaling system modulates neurotransmission and inflammation, among other physiological functions. Its newest member, α/β-hydrolase domain-containing 6 (ABHD6), has emerged as a promising therapeutic target to treat several devastating diseases, including epilepsy. Here, we review the molecular mechanisms that mediate and control eCB signaling and, within it, the specific role of ABHD6. We also discuss how ABHD6 controls the abundance of additional lipids and the trafficking of ionotropic receptors to plasma membranes. We finish with several unexplored questions regarding this novel enzyme. Our current understanding of the molecular mechanism and biological function of ABHD6 provides a strong foundation for the development of small-molecule therapeutics to treat devastating diseases.

KW - ABHD6

KW - endocannabinoids

KW - enzyme

KW - epilepsy

KW - neuroinflammation

KW - neurons

UR - http://www.scopus.com/inward/record.url?scp=85062471784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062471784&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2019.02.002

DO - 10.1016/j.tips.2019.02.002

M3 - Review article

C2 - 30853109

AN - SCOPUS:85062471784

SN - 0165-6147

VL - 40

SP - 267

EP - 277

JO - Trends in pharmacological sciences

JF - Trends in pharmacological sciences

IS - 4

ER -

ABHD6: Its Place in Endocannabinoid Signaling and Beyond

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this